Appointment of a new Director to the Board of Directors of Immune Biosolutions Inc.
We are thrilled to welcome a new director to the board of directors of Immune Biosolutions Inc: Mr. Nicholas Franco. The arrival of Mr. Franco is part of the company’s development strategy. With over 32 years of experience in the pharmaceutical industry, research, marketing, sales, and business development in several therapeutic areas, both domestically and internationally, “He will certainly bring a unique strategic perspective of the industry and a vision focused on value creation to the Board,” says Luc Paquet, CEO of the company.
Mr. Franco holds a bachelor’s degree in biochemistry and a master’s degree in business administration, strategic planning, and marketing from McGill University. He began his career at Sandoz/Novartis Pharma as a new product development manager, and then held various positions at Novartis Pharma AG, from International Brand Director to European Market Head. He then continued his career at Axcan Pharma SAS as Senior VP of International Commercial Operations, followed by Actelion (now Janssen Pulmonary Hypertension) as VP and Head of Business Development, and ended his corporate career at Janssen as EVP and Head of Business Development. He also served as Vice President of the Board of Interpharma (the Swiss association of innovative pharmaceutical companies).
“I am very happy to join the Board of Directors of Immune Biosolutions, a Quebec-based company dedicated to finding innovative solutions for targeting difficult-to-reach proteins involved in diseases, and to bring my over three decades of experience in the biopharmaceutical field,” says Nicholas Franco.
“We are extremely proud and excited to have him join us. His experience and strategic vision of the industry will certainly help us achieve our growth objectives in a constantly evolving market,” says Louise Proulx, Chairman of the Board of Immune Biosolutions.
About Immune Biosolutions Inc.
Immune Biosolutions is a company that utilizes the unique properties of the avian immune system to generate novel therapeutic antibodies for the development of immuno-therapies, notably in infectious diseases and cancer.
###
Luc Paquet
CEO
2650 rue Maximilien-Chagnon
Sherbrooke, Qc, Canada, J1E 0M8
